Clinical research suggests that the Autologous Vaccine works in a very complex way at the levels of cell-mediated and humoral immunity, and stimulates the formation and activation of T-helper cells. It is cultured from the patient’s own blood that represents his/her own unique internal bodily environment. The preparation follows procedures that favor the development of antigenic peptides and other immunogenic compounds aiming to enhance the body’s immune functions.
The vaccine is sterile. Since it is custom prepared from the patient’s own blood, side effects typically associated with other treatments are not experienced. A slight rise in temperature, fatigue, and tenderness in the tumor area are possible for a period of 6 to 48 hours after administration.
Experience has shown that the effectiveness of the vaccine, or of any vaccine, is enhanced when it is administered within a comprehensive biological treatment program.
Dr. Josef Issels pursued research on immunologic and microbiological aspects of cancer etiology since 1948. He established several research departments in his hospital from its inception in 1951. Already in the early years, Dr. Issels and his co-researchers developed cancer vaccines in laboratories located on the premises.
In 1970, the hospital grew from 85 to 120 patient beds and expanded its extensive research facilities into microbiological, immunological, dental departments, and the hyperthermia department, etc.
From 1958 until 1973, Dr. Franz Gerlach was Director of Research of the microbiology department of Dr. Issels’ hospital. Dr. Gerlach, was a professor of the University of Vienna, Austria, and represented Austria at the 1946 International Conference of Microbiology of Cancer. He worked at the Pasteur Institute in Paris, was a Fellow of the reputable Academy of Medicine in Paris, among other institutions, and was well known to oncologists all over the world for his research on mycoplasmas and cancer. Dr. Issels’ hospital became the only such institution of the era to conduct research on mycoplasmas in cancer and chronic degenerative diseases.
A variety of studies in Dr. Issels’ microbiology department confirmed that mycoplasma species can be causative or co-factors in the development of cancer. For example, after cell free depot inoculation of mycoplasmas under the skin of 209 albino mice, 90.9% developed all types of malignancies, whereas of 600 control animals which were not inoculated, only 0.83% developed cancer.
Recent research by reputable scientists such as Drs. S.C. Lo, Chief of Molecular Pathology at the Armed Forces Institute of Pathology in Washington, D.C., S. Tsai, D.J. Wear, J.W. Shih, B. Zhang, R. Dudler, C. Schmidhauser and others, suggests an association between mycoplasmas and malignancy, as well as with AIDS.
Drs. M. Nasralla, J. Haier, G.L. Nicolson, professor at M.D. Anderson Cancer Center, Houston, Texas, and the Institute for Molecular Medicine, Huntington Beach, California, et al. confirm the involvement of certain mycoplasma species in the Gulf War Syndrome, Chronic Fatigue Syndrome, Fibromyalgia, and Rheumatoid Arthritis.
For more than a century, international researchers have precisely documented certain microorganisms in human blood, body fluids and tissues, which were highly “pleomorphic”, i.e. they can appear in various developmental stages and in diverse forms while maintaining their essential characteristics.
When the host terrain deteriorates, they have been observed to transform from primitive structures into higher cyclogenetic structures. They can become pathogenic and may be causative or contributory factors in the development of malignancies, various chronic degenerative diseases and immune disorders. Some researchers have observed that disease causing higher cyclogenetic structures can be reversed by the administration of lower cyclogenetic structures.
Different scientists have given different names to these microorganism. However, they all have documented essential features in common: the microbes are stainable, cell wall deficient, virus-like and pleomorphic. They are classified as stealth pathogens.
Zur Biologie der Mykoplasmen und ueber ihre Beziehungen zu malignen Tumoren” Wiener Tieraerztliche Monatsschrift, 1970, No.6/7, 232-245.
“Participation of Mycoplasmas in Oncogenesis” 1975, Wiener Medizinische Wochenschrift No. 4, Suppl.26.
“Immunotherapy in Progressive Metastatic Cancer A Fifteen-Year Survival Follow-up” 1970, Clinical Trials Journal 7(3): 357-366, London.
“Cancer: A Second Opinion” 1999, Avery Publishing Group, New York.
Tsai S, Wear DJ, Shi W, Lo SC
“Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation “1995, Proc. Natl. Acad. Sci. USA; 92(22):10197-201.